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ABSTRACT
Introduction There is an urgent need to idenfy treatments 
for COVID-19 that reduce illness duration and hospital 
admission in those at higher risk of a longer illness course 
and complications.
Methods and analysis The Platform Randomised 
trial of INterventions against COVID-19 In older peoPLE 
trial is an open- label, multiarm, prospective, adaptive 
platform, randomised clinical trial to evaluate potential 
treatments for COVID-19 in the community. A master 
protocol governs the addition of new interventions as they 
become available, as well as the inclusion and cessation 
of existing intervention arms via frequent interim analyses. 
The first three interventions are hydroxychloroquine, 
azithromycin and doxycycline. Eligible participants must be 
symptomatic in the community with possible or confirmed 
COVID-19 that started in the preceding 14 days and either 
(1) aged 65 years and over or (2) aged 50–64 years with 
comorbidities. Recruitment is through general practice, 
health service helplines, COVID-19 ‘hot hubs’ and directly 
through the trial website. Participants are randomised to 
receive either usual care or a study drug plus usual care, 
and outcomes are collected via daily online symptom 
diary for 28 days from randomisation. The research team 
contacts participants and/or their study partner following 
days 7, 14 and 28 if the online diary is not completed. The 
trial has two coprimary endpoints: time to first self- report 
of feeling recovered from possible COVID-19 and hospital 
admission or death from possible COVID-19 infection, both 
within 28 days from randomisation. Prespecified interim 
analyses assess efficacy or futility of interventions and 
to modify randomisation probabilities that allocate more 
participants to interventions with better outcomes.
Ethics and dissemination Ethical approval Ref: 20/
SC/0158 South Central - Berkshire Research Ethics 
Committee; IRAS Project ID: 281958; EudraCT Number: 
2020-001209-22. Results will be presented to 
policymakers and at conferences and published in peer- 
reviewed journals.
Trial registration number ISRCTN86534580.
INTRODUCTION
The SARS- CoV-2, which causes COVID-19, 
has now infected over 98 million people 
globally, with over 2 million deaths.1 As of 23 
January 2021, 3 583 907 confirmed cases and 
Strengths and limitations of this study
 ► The adaptive platform design allows new interven-
tions to be added as they become available and for 
futile interventions or those with safety concerns to 
be stopped.
 ► Response adaptive randomisation means that more 
participants may be randomly assigned to better 
performing interventions.
 ► Eligible participants are able to participate regard-
less of where they receive their healthcare.
 ► The trial is open label and so will not be able to 
quantify possible placebo effects, especially regard-
ing patient- reported outcomes.
 ► The primary analysis will include those meeting syn-
dromic criteria for COVID-19.
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95 981 deaths had been reported in the UK.23 There is an 
urgent need to identify interventions against COVID-19 
suitable for wide use in the community that have been 
proven to be effective in reducing symptom duration 
or hospitalisation.4 We urgently need to know whether 
potential COVID-19 treatments that are available for 
rapid pragmatic evaluation might modify the course of 
COVID-19 infections, particularly among those who are 
at higher risk of complications, such as those aged 50 
years and over with comorbidity and those aged 65 years 
and over.5–8
The majority of reported trials have been conducted in 
hospital settings, and there is little evidence from commu-
nity settings, where most people with COVID-19 receive 
care and where deployment of effective early treatment 
could speed time to recovery and reduce complications.4 9
We established a multiarm, adaptive platform, 
randomised controlled trial for community treatment of 
COVID-19 syndromic illness in people at higher risk of an 
adverse illness course.
Objectives
To assess the effectiveness of treatments in reducing time 
to feeling recovered and the need for hospital admission 
(or death) among patients with possible COVID-19 in the 




The Platform Randomised trial of INterventions against 
COVID-19 In older peoPLE (PRINCIPLE) study is an 
open- label, multiarm, prospective, adaptive platform, 
randomised clinical trial in community care. A ‘platform 
trial’ is an adaptive clinical trial in which multiple treat-
ments for the same disease are tested simultaneously. The 
platform trial design allows further interventions to be 
added while the trial is in progress and for futile interven-
tions to be dropped via frequent interim analyses.10–12 In 
addition, response adaptive randomisation is used to allo-
cate more participants to interventions resulting in better 
outcomes, potentially leading to more rapid and efficient 
discovery of beneficial interventions.
Participants are randomised to either usual care or 
usual care plus a study drug. Usual care is not speci-
fied or mandated in the protocol but refers to the care 
that participants receive, decided on by the responsible 
treating clinician. The first three interventions included 
are hydroxychloroquine, azithromycin and doxycycline. 
A master protocol13 defines prospective decision criteria 
to allow for dropping a treatment for futility, declaring 
a treatment superior, or adding a new treatment to be 
tested. If at any point, usual care plus a study drug is 
deemed superior to usual care alone for both the recovery 
and hospitalisation coprimary endpoints (see further), 
the superior treatment will be incorporated into usual 
care as the new standard of care. Because the process of 
dropping and adding treatments may be ongoing for an 
indefinite period of time, platform trials may be better 
conceived of as a process rather than a single clinical trial.
Ethics and dissemination
All participants provide informed consent, online or by 
telephone, before participation. An independent Data 
Monitoring and Safety Committee (DMSC) reviews 
emerging data from the Statistical Analysis Commitee 
(SAC) and communicates key decisions to the Trial 
Steering Committee (TSC), who advises the Trial 
Management Group (TMG) and also provides oversight 
of the trial. Manuscripts with the results of the primary 
outcomes will be published in peer- reviewed journals.
Patient and public involvement
Five women and two men in our target recruitment 
age group with an interest in diagnosis and manage-
ment of infections reviewed the patient- facing materials, 
including outcomes, and trial delivery plans. They were 
very supportive of including a nominated support person 
to help the recruited patients with trial participation. 
They suggested edits for clarity to the patient informa-
tion sheet and daily diary. They were keen to document 
their strong support of work to evaluate possible treat-
ments for COVID-19 in community settings. Two public 
contributors serve on the TSC and have reviewed patient- 
facing materials and commented on study design and 
dissemination.
Study setting
The trial is managed by the University of Oxford Primary 
Care and Vaccines Collaborative Clinical Trials Unit (PCV- 
CTU),14 supported by the National Institute of Health 
Research Clinical Research Network and the National 
Institute of Health Research and is implemented in the 
UK through general practices (GPs), the Primary Care 
specialty of the Clinical Research Network, community- 
based COVID-19 services, including telehealth services 
such as the UK National Health Service (NHS) 111 
and community clinics and testing centres that provide 
COVID-19 assessments to community- based patients. All 
mandated study procedures can be conducted remotely, 
in keeping with the current self- isolation guidance for 
patients with possible COVID-19 in the community.15
Eligibility criteria
To facilitate early intervention, and in keeping with the 
changing situations in primary care, the trial enrols partic-
ipants with possible COVID-19 irrespective of whether 
they have had confirmatory SARS- CoV-2 testing. Possible 
COVID-19 is determined using the United Kingdom NHS 
definition of high temperature and/or a new, continuous 
cough and/or a change in sense of smell or taste. Patients 
with other symptoms consistent with COVID-19 and a 
positive SARS- CoV-2 PCR test are also eligible. Symptoms 
must have started within the previous 14 days and be 
ongoing at the time of enrolment. To target patients at 
high risk of morbidity and mortality from COVID-19, the 
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trial enrols people aged 65 years and over or 50–64 years 
with comorbidities (table 1). Patients with contraindica-
tions to a trial drug are excluded from enrolment into 
that particular intervention arm but remain eligible for 
randomisation into other arms. Patients must be eligible 
for the usual care arm and at least one intervention arm 
in order to take part in the trial.
Study procedures
Recruitment
The trial is low burden for participants and those 
recruiting into the trial. All health and social care profes-
sionals and members of the public are able to refer 
potential participants to the study website, or suggest they 
contact the trial team directly by telephone or email. They 
may also send a text message or letter to patients who are 
potentially eligible to let them know that if they have, or 
should they develop, symptoms, they may be eligible for 
the trial, and are given a link to the trial website and free-
phone number. Participants may also hear about the trial 
through media and can self- refer via the study website 
and freephone number.
Screening, informed consent and enrolment
An online screening, eligibility and consent procedure is 
used. Patients without internet access or requiring help 
with the online procedures can be assisted by a clini-
cian or the trial team by telephone. Interested patients 
can access the patient information leaflet on the trial 
website or by telephoning the trial team. The patient 
information leaflet is available in English and nine other 
commonly spoken languages in the UK. After reading 
the patient information leaflet, potential participants 
are screened through an eligibility questionnaire and 
asked to complete an online consent form. The trial 
team is then notified electronically and assess the partici-
pant’s eligibility using information from the participant’s 
medical records. If they are unable to access the partici-
pant’s medical records, the participant’s GP is contacted 
for further information. Healthcare providers can also 
choose to fully confirm eligibility before referring the 
patient to the trial team.
In addition, participants can be screened and enrolled 
by their GP at participating primary care practices. The 
participant and GP can use the online screening, consent 
and randomisation procedures, with the GP confirming 
eligibility using the patient’s medical record.
Participants are asked to nominate and include contact 
details for a study partner (eg, family member) who may 
provide assistance in completing trial procedures and 
in providing follow up information. Nominating a study 
partner is not a requirement of participation.
Randomisation and blinding
After informed consent is obtained and eligibility has 
been confirmed, participants are randomised using a 
rapid, secure, web- based randomisation system called 
Sortition (Oxford University Innovation). The partici-
pant, specific members of the trial team and participant’s 
GP are notified electronically regarding treatment alloca-
tion. The trial started by using randomisation proportions 
but subsequently uses response adaptive randomisation 
via interim analyses to allocate more subjects to the inter-
ventions with better outcomes (see Statistical methods).
This is an open- label trial. Participants and recruiting 
clinicians know the participant’s allocation. Therefore, 
no unblinding or code breaking is required. However, 
those managing the data are blind to participant allo-
cation, and the trial team and recruiters are blinded 
to emerging results. Only those on the DMSC and the 
unblinding statisticians have access to the unblinded 
interim analysis results. Any changes made in the alloca-
tion probability are blind to the trial team apart from the 
programmer who needs to implement this to the rando-
misation system.
Baseline assessments
During screening and enrolment, participants record 
baseline demographic and medical data, which may 
be supplemented by a clinician using data from the 
participant’s summary medical care record (table 2). 
Participants are also asked to complete the WHO – Five 
Well- Being Index (WHO-5), a simple instrument that 
has been validated for measuring well- being over time.16 
Table 1 Current inclusion and exclusion criteria for the 
PRINCIPLE trial
Inclusion criteria Exclusion criteria*
 ► Willing and able to give informed 
consent for participation in the 
study.
 ► Willing to comply with all trial 
procedures.
 ► Symptoms of possible COVID-19 
(any of fever, cough, change in 
taste/smell or other symptoms with 
a positive SARS- CoV-2 test). Onset 
of symptoms or a positive test for 
SARS- CoV-2 with symptoms of 
COVID-19 must be within the last 
14 days.
 ► Patients aged ≥65 years.
OR
Patients aged ≥50–64 years with any 
of the following listed comorbidities:
 ► Known weakened immune 
system due to a serious illness or 
medication (eg, chemotherapy).
 ► Known heart disease and/or a 
diagnosis of high blood pressure.
 ► Known asthma or lung disease.
 ► Known diabetes.
 ► Known mild hepatic impairment.
 ► Known stroke or neurological 
problem.
 ► Self- report obesity or body mass 
index ≥35 kg/m2.
 ► Currently admitted in 
hospital.
 ► Almost recovered 
(generally much 
improved and 
symptoms now mild or 
almost absent).
 ► Judgement of the 
recruiting clinician 
deems ineligible.
 ► Patient already taking 
an intervention arm 
medication.
 ► Previous randomisation 
to an arm of the 
PRINCIPLE trial.
*Exclusion criteria for specific intervention arms detailed in intervention 
specific appendices to the master protocol.
PRINCIPLE, Platform Randomised trial of INterventions against 
COVID-19 In older peoPLE.
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Participants are also asked to provide a self- swab for 
SARS- CoV-2 testing, when available, and report the result 
of any recent test results for the virus.
Interventions
Trial drugs tested in PRINCIPLE are considered to have 
the potential for widespread and generally safe use in 
primary care. GPs may be able to issue study medication 
directly to participants or prescribe it for collection at a 
pharmacy. Medication may also be delivered to patients 
directly from the trial team. Side effects are reported 
through the online diary, telephone calls to the trial team 
and through electronic medical care record review. More 
details regarding intervention treatments, including 
the rationale for testing them in the trial, contraindica-
tions and eligibility criteria, are detailed in Intervention 
Specific Appendices to the master protocol.
Due to the urgent need for rapid trial implementa-
tion in the ongoing pandemic, this is a pragmatic, open- 
label trial with no placebo control.12 17–19 The current 
control arm in PRINCIPLE is usual care. Current UK 
guidelines for managing possible COVID-19 infections 
in the community do not currently recommend the 
routine use of any antiviral drugs nor antibiotics unless 
there are signs of pneumonia.20 Clinicians make clinical 
judgements about best treatment on an individual basis, 
but care is usually supportive to begin with.20 In all study 
arms, participants will receive the usual care that they 
would normally receive following UK NHS practice and 
guidelines but with the addition of a trial drug in inter-
vention arms. The trial team is not involved in clinical 
care or treatment decisions.
Follow-up
All participants receive a call from the trial team 3 days 
after enrolment to confirm the receipt of study materials 
including swab and medication (if randomised to a study 
drug) and to address any questions. For the 28 days after 
enrolment, participants and/or their study partner are 
asked to use a daily online diary to record whether they 
feel recovered (‘Do you feel recovered today? (ie, symp-
toms associated with illness are no longer a problem’)); 
how well they feel (‘How well are you feeling today? 
Please rate how you are feeling now using a scale of 1–10, 
where 1 is the worst you can imagine, and 10 is feeling 
the best you can imagine’); trial medication adherence; 
presence of individual symptoms (fever, cough, short-
ness of breath, muscle ache, nausea/vomiting, diarrhoea, 
generally feeling unwell, all rated as ‘no problem’, ‘mild 
problem’, ‘moderate problem’ or ‘severe problem’); use 
of other medicines to control symptoms, contacts with 
health services; and new infections in the household. In 
addition, at days 14 and 28, the WHO-5 questionnaire 
is administered for follow- up. Participants and/or their 
Table 2 Schedule of evaluation in the PRINCIPLE trial
Study period
Screening Enrolment Follow- up
Days in study 0 0 1–28 days 29 days–onwards
Participant completes screening, eligibility and 
baseline questionnaire
× ×     
Clinician completes eligibility* × ×     
Informed consent* × ×     
Demographics, medical history and test results*§ × ×     
Concomitant medication × ×   ×
Randomisation   ×     
Self- swab for SARS- CoV-2 testing   ×     
Dispensing of trial drugs†   × ×   
Usual clinical care§ × × ×   
Daily questionnaire   ×   
WHO- Five Well- Being Index   × Days 14 and 28   
SARS- CoV-2 serology test if available and obtainable     ×
Telephone interview: qualitative study     ×‡
Adherence   ×   
Adverse event assessments   × ×
*Online or by phone.
†In trial drug arms only.
‡For subset of patient participants.
§Retrospective data collection by study team.
PRINCIPLE, Platform Randomised trial of INterventions against COVID-19 In older peoPLE.
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study partner who have not entered data online are 
contacted by telephone on days 7, 14 and 28 to obtain 
information about hospital admission, recovery, presence 
and severity of symptoms, and healthcare utilisation.
We also obtain consent from participants to ascertain 
relevant outcome data from general practice and hospital 
records about hospital assessments, COVID-19 related 
admissions, oxygen use, intensive care and mechanical 
ventilation, and longer term outcomes relevant to COVID-
19. Trial implementation began through the Oxford- 
Royal College of General Practitioners Research and 
Surveillance Network, which has the capacity to extract 
patient information from the clinical records and provide 
a trial observatory to report on trial progress and a dash-
board to flag the number of potentially eligible patients 
in each practice (https:// clininf. eu/ index. php/ prin-
ciple).21 GP surgeries outside this network may also be 
contacted separately by the trial team to request specific 
data from participants’ primary care medical records.
Sample handling
We endeavour to provide participants with a self- sampling 
kits for evidence of SARS- Cov-2 through their practice, 
the trial team, Public Health England or other central 
service to be taken at baseline. However, this depends on 
swab availability. If swabbing kits are unavailable, patients 
may still participate in the trial and are included in the 
intention- to- treat analysis. We also seek optional consent 
from participants to be contacted about providing a 
sample for serological testing for SARS- CoV-2 infection 
during convalescence.
Study outcomes
There are two coprimary endpoints. The first is time to 
recovery from possible COVID-19 infection within 28 days 
from randomisation, with time to recovery defined as the 
first instance that a participant reports feeling recovered. 
Although a number of secondary outcomes also evaluate 
recovery, self- report of feeling recovered was chosen 
for the primary outcome as the most direct measure of 
patient experience. The second is hospital admission 
or death within 28 days of randomisation. Decision to 
hospitalise is made by clinicians independent of the trial. 
Secondary outcome measures are listed in table 3.
Data collection and management
Data are entered into the participant’s electronic case 
report form by the participant, study partner or trial 
team using an OpenClinica database via Sentry. Open-
Clinica is stored on a secure server and meets FDA part 
11B standards. This includes safety data, laboratory data 
and outcome data. Sentry is an online secure data entry 
system developed in- house at the PCV- CCTU and hosted 
at Oxford. It is designed to collect sensitive data, such as 
participant contact details, and securely retain them sepa-
rately from a trial’s clinical data. To protect confidenti-
ality, all study- specific documents other than the signed 
consent form refer to the participant using their study 
participant number rather than their name.
Statistical methods
Coprimary outcomes analysis
Full statistical methods are detailed in a master statis-
tical analysis plan. In brief, the first coprimary analysis 
is a Bayesian piecewise exponential of time to recovery 
regressed on treatment and stratification covariates (age, 
comorbidity or high risk). The second coprimary analysis 
is a Bayesian logistic regression model of hospitalisation/
death regressed on treatment and stratification covari-
ates. The coprimary outcomes are evaluated using a ‘gate- 
keeping’ strategy. For a given treatment, the hypothesis 
for the time to recovery endpoint is evaluated first, and 
if the recovery null hypothesis is rejected, the hypothesis 
for the second coprimary endpoint of hospitalisation/
death is evaluated. This gate- keeping strategy preserves 
the overall type I error of the primary endpoints without 
additional adjustments for multiple hypotheses.
The prespecified design allows adaptations to the trial 
based on the observed data. These adaptations include 
the declaration of success or futility of an intervention at 
an interim analysis, the addition or removal of treatment 
arms and changes in the randomisation probabilities. 
At each interim analysis, all enrolled intervention arms 
will be evaluated for success or futility using the Bayesian 
primary analysis. If the Bayesian posterior probability 
of superiority of a given intervention over usual care is 
greater than or equal to 0.99 for the recovery endpoint 
and greater than or equal to 0.975 for the hospitalisation 
endpoint, superiority versus usual care will be declared 
on both endpoints, in which case the superior arm will 
replace the usual care arm as the new standard of care. 
The superiority thresholds of 0.99 and 0.975 for the first 
and second coprimary hypotheses, respectively, were 
determined a priori via simulation in order to control the 
one- sided type I error of the study at approximately 0.025.
If the Bayesian posterior probability of a clinically mean-
ingful treatment effect (≥1.5 days) on time to recovery is 
sufficiently small (<0.05), the intervention arm will be 
dropped from the study for futility. If there are no other 
intervention arms available, the trial will be suspended; 
otherwise accrual continues to the remaining treatment 
arms.
Response adaptive randomisation
Prior to the first interim analysis, allocation will be equal 
among all treatment arms, with randomisation stratified 
by age (<65 or ≥65) and comorbidity. Response adaptive 
randomisation is activated at the time of the first interim 
analysis if there are at least two active interventions in 
the trial. When response adaptive randomisation is acti-
vated, the usual care arm will continue to receive a fixed 
allocation of 1/Z, where Z is the total number of treat-
ment arms in the study. The remaining (Z-1)/Z alloca-
tion probability will be divided among the intervention 
arms based on interim response adaptive randomisation 
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probabilities. This is done by fitting the primary analysis 
model for time to recovery at an interim analysis and 
defining new randomisation probabilities proportional 
to the probability that each intervention is optimal with 
respect to the first coprimary endpoint. The purpose of 
implementing response adaptive randomisation is to allo-
cate more participants to the intervention arms with the 
better observed outcomes (relative to usual care).
Sample size
Given the open, ‘perpetual’ trial structure, the trial does 
not have a finite ending based on sample size. We esti-
mate that approximately 400 participants per arm (800 
participants total if only a single intervention vs usual 
care) will be required to provide 90% power for detecting 
an approximate difference of 2 days in median recovery 
time. We estimate that approximately 1500 participants 
per arm (3000 participants total if only a single inter-
vention vs usual care) will be required to provide 90% 
power for detecting a 50% reduction in the relative risk 
of hospitalisation and/or death. A key feature of the 
adaptive design is the ability to adapt the sample size to 
the observed data, thus addressing the primary hypoth-
esis as quickly and as efficiently as possible.
Virtual trial simulations
Because of the adaptive platform trial structure, there 
exists no simple formula(e) to calculate power and type 
I error (false positive rate). Hence, virtual trial simu-
lations are used to fully characterise and quantify the 
power and type I error of the design. These simulations 
include a comprehensive evaluation of trial perfor-
mance across a wide range of assumptions (eg, under-
lying distribution of outcome in control arm, treatment 
effect, accrual rates, etc). This includes summaries 
regarding the number of subjects required to make a 
success or futility conclusion for each intervention. For 
example, we quantify the probability of claiming supe-
riority at the first and each of the subsequent interim 
analyses. Details of the simulations are provided in an 
Adaptive Design Report.
Table 3 Study outcomes in the PRINCIPLE trial
Primary outcome measures Data source Timepoint(s)
Time to recovery defined as the first instance that a 
participant reports feeling recovered from possible 
COVID-19
Patient or study partner report. Within 28 days.
Hospital admission or death Patient or study partner self- report and 
medical record review.
Within 28 days.
Secondary outcomes     
Duration of severe symptoms measured through 
daily diary
Self- report using online diary or 
telephone call/text.
Daily online diary or telephone/
text at days 7, 14 and 28 if no 
online data received.Patient- reported illness severity
Number of contacts with the health services Participant of study partner report 
using online diary, or telephone call/
text and medical record review in 
primary care and hospital care.
Daily online diary or telephone/
text at days 7, 14 and 28 if no 
online data received
primary care and hospital 
records.
Additional antibiotic use
Hospital assessment without admission
Oxygen administration
Intensive care unit admission
Mechanical ventilation
(5–8 allows for an estimation of a version of the 
WHO Clinical Progression Ordinal Scale)
Duration of hospital admission
WHO- Five Well- Being Index WHO- Five Well- Being Index. Baseline and days 14 and 
28 either via online diary or 
telephone
To determine if effects are specific who test positive 
for SARS- CoV-2
Swab results and optional serology for 
SARS- CoV-2 to determine an ‘Intention 
to Treat Infected’ group within the 
overall cohort for sub analysis.
Swabs from enrolment and/or 
day 5. Convalescent serology.
Qualitative substudy     
Patient experiences of consulting, being tested and 
taking (trial) medication for possible COVID-19
Telephone interview with participant. After 28 days.
To explore healthcare professionals’ views of taking 
part in research during pandemics
Telephone interview with healthcare 
professional.
At least 2 months after practice 
started recruiting.
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Primary analysis population
The primary intention- to- treat analysis population is defined 
as all randomised participants according to the group they 
were randomly allocated to, regardless of deviation from 
protocol and irrespective of their COVID-19 status.
Secondary endpoints/analyses
Secondary outcomes include duration of severe symp-
toms, contacts with health services, antibiotic prescrip-
tions, oxygen administration, intensive care admission, 
mechanical ventilation (allowing for an estimation of a 
version of the WHO Clinical Progression Ordinal Scale) 
and self- reported well- being (table 3). Participants 
recruited into the study are asked to indicate if they have 
already had a positive test and to provide a self- swab to 
confirm SARS- CoV-2 infection, allowing ‘intention to 
treat infected’ analyses to be performed among those with 
evidence of a positive test. Blood tests may also be taken 
for evidence of having had COVID-19 illness. Hence, the 
primary analyses and key secondary analyses can be repli-
cated on this ‘intention to treat infected’ population.
Qualitative substudy
We will perform semistructured telephone interviews with 
a subset of participants after they have competed 28 days 
of follow- up to ask about illness perceptions, reasons for 
consulting (if applicable), experiences of the consultation, 
the SARS- CoV-2 testing process (and result where the partic-
ipant has been notified) and medication adherence. The 
topic guide will be informed by the Common Sense Model, 
which describes how people perceive and cope with symp-
toms of illness.22 We will conduct interviews with approxi-
mately 30–40 participants in total. We will also interview a 
sample of healthcare service, location and practice size to 
achieve a wide range of views of carrying out trial activities, 
recruiting patients and the work required to set up a clinical 
trial during a pandemic. We will purposively select approxi-
mately 20–25 healthcare workers based on job role, health-
care service and location to achieve a wide range of views. 
Interviews will be transcribed and thematically analysed 
using NVivo 12 software.
Ethics, approvals, monitoring and dissemination
The trial has been approved by the University of 
Oxford Clinical Trials Research & Governance team as 
study sponsor, the South Central – Berkshire Research 
Ethics Committee (20/SC/0158), the Health Research 
Authority (HRA) and the UK Medicines and Health-
care products Regulatory Agency (MHRA). The Trial 
has received Urgent Public Health Level 1a Priority 
Status by the National Institute of Health Research. 
The University has a specialist insurance policy in 
place, which would operate in the event of any partici-
pant suffering harm as a result of their involvement in 
the research.
An independent DMSC independent from the sponsor 
and without competing interests and comprised of three 
senior medical statisticians and two senior primary care 
researchers with expertise in respiratory infections, 
reviews interim analyses of accruing data to ensure the 
rights, safety and well- being of the trial participants 
and advises the TSC about whether interim analyses 
recieved from the SAC demonstrate futility or success 
of interventions. Along with the TSC, the DSMC makes 
recommendations about how the study is operating, 
any ethical or safety issues and consideres any data from 
other relevant studies that might impact the trial. The 
TSC advises the TMG accordingly and has oversight 
of trial delivery. Any breaches in confidentiality, study 
protocol or adverse events attributable to this study are 
reported to the Research Ethics Committee and the 
MHRA where appropriate. Eligible patients are asked 
to provide informed consent for study procedures. All 
participants receive a £20 voucher as a token of recog-
nition their contribution to the study. Trial results will 
be presented at national and international conferences 
and published in academic, peer- reviewed journals.
A risk assessment and monitoring plan was prepared 
before the study opened and is reviewed as necessary to 
reflect significant changes to the protocol or outcomes 
of monitoring activities. Monitoring is performed by the 
PCV- CTU Quality Assurance Manager or delegate.
Safety monitoring
All symptoms, medication side effects and Serious Adverse 
Events (SAEs) are collected from participant daily diaries, 
calls to participants/study partners, medical records, 
notes reviews and extracts form routinely collected 
medical records.
SAE information is analysed as part of the interim 
and whole trial analysis and is reviewed at each DMSC 
meeting.
Trial status
PRINCIPLE was registered on the ISRCTN registry 
(ISRCTN86534580) on the 22 March 2020. Enrolment 




Evidence- based interventions to treat COVID-19 in 
community settings are urgently required to reduce the 
health and social impacts of this pandemic.4 We outline 
an open- label, multiarm, prospective, adaptive platform, 
randomised clinical trial that aims to rapidly evaluate 
multiple drug treatments for COVID-19 among people at 
higher risk of complications in the community.
Comparison with other studies
Two other national platform trials are assessing poten-
tial COVID-19 treatments in the UK.23 The REMAP- CAP 
trial (NCT02735707) is focusing on patients admitted 
to intensive care units. Treatments under investigation 
have included lopinavir/ritonavir, hydroxychloroquine, 
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interferon- beta- 1a and an interleukin-1 receptor antat-
gonist.24 The RECOVERY trial (ISRCTN50189673) is 
focusing on hospital inpatients, and investigatory treat-
ments have included lopinavir/ritonavir, dexamethasone, 
hydroxychloroquine and azithromycin with usual hospital 
care.25 Together, these trials are assessing COVID-19 
interventions across a range of clinical and community 
settings. Trials of community use of hydroxychloroquine 
in the community have been reported,26 27 but there are 
few other recruiting platform trials of community- based 
treatments for COVID-19 capable of evalauting multiple 
intervetions in an ongoing way.
Strengths and limitations
A major strength of PRINCIPLE is its community care 
focus, positioning it to test interventions for COVID-19 
at earlier and milder stages of illness. As an ‘in- pan-
demic’ trial, we have designed PRINCIPLE to minimise 
the burden on existing healthcare services that are often 
already under strain and have removed the requirement 
for face- to- face contact for the purposes of the trial to 
minimise the risk of SARS- CoV-2 transmission.28 The trial 
is potentially open to anyone in a participating jurisdic-
tion who meets eligibility requirements. Furthermore, 
the use of routinely collected data from electronic health 
records may complement the capture of trial outcomes 
and safety monitoring. The adaptive design allows flexi-
bility as the pandemic evolves, providing the capability to 
rapidly test new interventions as they become available. 
Interventions suitable for pragmatic evaluation in the 
PRINCIPLE trial have a favourable safety profile and may 
be suitable for widespread deployment in primary care 
settings. Therefore, if an intervention proves effective, 
rapid scale up should be achievable within the UK NHS 
and potentially also other settings.29
A potential weakness is the inclusion of patients with 
possible COVID-19, rather than laboratory confirmed 
SARS- CoV-2 infection. However, this reflects clinical 
practice during the time the participants were recruited, 
where some were managed on the basis of their clinical 
syndrome, in the absence of immediate confirmatory swab 
result as swab testing has not always been available during 
the conduct of the trial. Our eligibility criteria are based 
on the UK case definition for primary care,20 and we will 
use swab test results, where available, to identify positive 
SARS- CoV-2 cases for relevant secondary and exploratory 
analyses in the SARS- CoV-2 positive subgroup.
We deliberately chose to conduct a pragmatic, open- 
label trial in the context of everyday practice becasue 
the study hypothesises that the addtion of a medication 
being investigated will imporve outocmes over an above 
routine ususal care without that medication, and usual 
care does not involve provision of a placebo medication. 
Effect sizes identified by placebo- controlled, efficacy 
studies with tight inclusion criteria might not be repro-
duced in routine care,17 30 31 and it was not feasible to 
rapidly produce placebo for multiple drug interventions 
in this ‘in- pandemic’ platform trial. This pragmatic, open 
trial design makes our findings more likely to reflect 
real- world effects in community care, because knowl-
edge of the medication one is taking could affect subse-
quent help seeking, including presentation at hospitals. 
Capturing the effect of an intervention on help seeking 
is an important element in evaluating the consequences 
of its use. However, the design does not allow us to deter-
mine mechanisms of action, for example, how much of 
the observed effect can be attributed to the biological 
effects of the drug treatment or to a placebo effect. Meta- 
analyses of placebo controlled trials of oseltamivir for 
influenza- like illness found an average benefit of about a 
day reduction in symptoms.32 33 This is similar to the esti-
mate of average benefit obtained in a large, open multina-
tional trial of oseltamivir for infleunza- like illness.12 The 
lack of placebo is unlikely to significantly affect ‘harder’ 
outcomes such as hospitalisation and death, which form 
part of the PRINCIPLE trial coprimary outcome. In prag-
matic trials, the implementation of treatment strategies 
should resemble clinical practice as closely as possible.30 34
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